Your browser doesn't support javascript.
loading
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda, Christof M; Ding, Ying; Kelly, Ronan P; Garhyan, Parag; Shi, Chunxue; Lim, Chay Ngee; Fu, Haoda; Watson, David E; Lewin, Andrew J; Landschulz, William H; Deeg, Mark A; Moller, David E; Hardy, Thomas A.
Afiliação
  • Kazda CM; Eli Lilly and Company, Suresnes, France kazda_christof@lilly.com.
  • Ding Y; Eli Lilly and Company, Indianapolis, IN.
  • Kelly RP; Lilly-NUS Centre for Clinical Pharmacology, Singapore.
  • Garhyan P; Eli Lilly and Company, Indianapolis, IN.
  • Shi C; inVentiv Health Clinical, Clarksville, MD.
  • Lim CN; Eli Lilly and Company, Indianapolis, IN.
  • Fu H; Eli Lilly and Company, Indianapolis, IN.
  • Watson DE; Eli Lilly and Company, Indianapolis, IN.
  • Lewin AJ; National Research Institute, Los Angeles, CA.
  • Landschulz WH; Eli Lilly and Company, Indianapolis, IN.
  • Deeg MA; Eli Lilly and Company, Indianapolis, IN.
  • Moller DE; Eli Lilly and Company, Indianapolis, IN.
  • Hardy TA; Eli Lilly and Company, Indianapolis, IN.
Diabetes Care ; 39(11): e199-e200, 2016 11.
Article em En | MEDLINE | ID: mdl-27926898
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Glucagon / Diabetes Mellitus Tipo 2 Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Glucagon / Diabetes Mellitus Tipo 2 Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article